HAOHAI BIOTEC (06826) Plans to Acquire Approximately 19.8% Stake in Jiangxi Ruiji Bioengineering

Stock News

Dec 12, 2025

HAOHAI BIOTEC (06826) announced on December 12, 2025, that the company and Zhong Xiaoyan intend to acquire approximately 19.8% and 2.4554% equity stakes, respectively, in Jiangxi Ruiji Bioengineering Co., Ltd. The transaction amounts to approximately RMB 38.3515 million and RMB 4.756 million, respectively.

The target company's products are primarily used in orthopedic and ophthalmic applications, including tendon injury repair, ocular surface burns, wound and lesion repair, as well as implantation and support post-lacrimal duct obstruction probing.

By investing in the target company and securing its product distribution rights in China, HAOHAI BIOTEC will enter the high-value-added medical device market for biological amniotic membranes. This move complements the group's existing product portfolio and expands its business presence in orthopedics and ophthalmology.

Additionally, the target company's amniotic membrane materials, which possess human-derived biological properties, provide critical technology and material foundations for the group in regenerative medicine and tissue engineering. This acquisition is expected to drive future product innovation and technological advancements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1129189007"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129189007\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129189007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129189007","market":"nz","top_or_hot":-1,"title":"HAOHAI BIOTEC (06826) Plans to Acquire Approximately 19.8% Stake in Jiangxi Ruiji Bioengineering","media":"Stock News","content":"<p>HAOHAI BIOTEC (06826) announced on December 12, 2025, that the company and Zhong Xiaoyan intend to acquire approximately 19.8% and 2.4554% equity stakes, respectively, in Jiangxi Ruiji Bioengineering Co., Ltd. The transaction amounts to approximately RMB 38.3515 million and RMB 4.756 million, respectively.</p>\n<p>The target company's products are primarily used in orthopedic and ophthalmic applications, including tendon injury repair, ocular surface burns, wound and lesion repair, as well as implantation and support post-lacrimal duct obstruction probing.</p>\n<p>By investing in the target company and securing its product distribution rights in China, HAOHAI BIOTEC will enter the high-value-added medical device market for biological amniotic membranes. This move complements the group's existing product portfolio and expands its business presence in orthopedics and ophthalmology.</p>\n<p>Additionally, the target company's amniotic membrane materials, which possess human-derived biological properties, provide critical technology and material foundations for the group in regenerative medicine and tissue engineering. This acquisition is expected to drive future product innovation and technological advancements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAOHAI BIOTEC (06826) Plans to Acquire Approximately 19.8% Stake in Jiangxi Ruiji Bioengineering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAOHAI BIOTEC (06826) Plans to Acquire Approximately 19.8% Stake in Jiangxi Ruiji Bioengineering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HAOHAI BIOTEC (06826) announced on December 12, 2025, that the company and Zhong Xiaoyan intend to acquire approximately 19.8% and 2.4554% equity stakes, respectively, in Jiangxi Ruiji Bioengineering Co., Ltd. The transaction amounts to approximately RMB 38.3515 million and RMB 4.756 million, respectively.</p>\n<p>The target company's products are primarily used in orthopedic and ophthalmic applications, including tendon injury repair, ocular surface burns, wound and lesion repair, as well as implantation and support post-lacrimal duct obstruction probing.</p>\n<p>By investing in the target company and securing its product distribution rights in China, HAOHAI BIOTEC will enter the high-value-added medical device market for biological amniotic membranes. This move complements the group's existing product portfolio and expands its business presence in orthopedics and ophthalmology.</p>\n<p>Additionally, the target company's amniotic membrane materials, which possess human-derived biological properties, provide critical technology and material foundations for the group in regenerative medicine and tissue engineering. This acquisition is expected to drive future product innovation and technological advancements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1129189007","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129189007","pubTimestamp":1765542980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HAOHAI BIOTEC (06826) announced on December 12, 2025, that the company and Zhong Xiaoyan intend to acquire approximately 19.8% and 2.4554% equity stakes, respectively, in Jiangxi Ruiji Bioengineering...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06826":"昊海生物科技","BK1593":"医美概念股"},"translate_title":"昊海生科(06826)拟收购江西瑞吉生物工程约19.8%股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06826":1},"content_text":"HAOHAI BIOTEC (06826) announced on December 12, 2025, that the company and Zhong Xiaoyan intend to acquire approximately 19.8% and 2.4554% equity stakes, respectively, in Jiangxi Ruiji Bioengineering Co., Ltd. The transaction amounts to approximately RMB 38.3515 million and RMB 4.756 million, respectively.\nThe target company's products are primarily used in orthopedic and ophthalmic applications, including tendon injury repair, ocular surface burns, wound and lesion repair, as well as implantation and support post-lacrimal duct obstruction probing.\nBy investing in the target company and securing its product distribution rights in China, HAOHAI BIOTEC will enter the high-value-added medical device market for biological amniotic membranes. This move complements the group's existing product portfolio and expands its business presence in orthopedics and ophthalmology.\nAdditionally, the target company's amniotic membrane materials, which possess human-derived biological properties, provide critical technology and material foundations for the group in regenerative medicine and tissue engineering. This acquisition is expected to drive future product innovation and technological advancements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}